Kate Gelperin

790 total citations
17 papers, 449 citations indexed

About

Kate Gelperin is a scholar working on Public Health, Environmental and Occupational Health, Cardiology and Cardiovascular Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Kate Gelperin has authored 17 papers receiving a total of 449 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Public Health, Environmental and Occupational Health, 5 papers in Cardiology and Cardiovascular Medicine and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Kate Gelperin's work include Heart Failure Treatment and Management (5 papers), Pregnancy and Medication Impact (5 papers) and Blood Pressure and Hypertension Studies (3 papers). Kate Gelperin is often cited by papers focused on Heart Failure Treatment and Management (5 papers), Pregnancy and Medication Impact (5 papers) and Blood Pressure and Hypertension Studies (3 papers). Kate Gelperin collaborates with scholars based in United States, Vietnam and Sweden. Kate Gelperin's co-authors include Steven T. Bird, Rosemary Johann‐Liang, Andrew D. Mosholder, Tarek A. Hammad, Mel Blumenthal, John Ilgenfritz, Leyla Şahin, Leif Erhardt, Lockwood G. Taylor and Christian Hampp and has published in prestigious journals such as JAMA, Annals of Internal Medicine and PEDIATRICS.

In The Last Decade

Kate Gelperin

17 papers receiving 434 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kate Gelperin United States 11 107 89 84 72 52 17 449
Michael Kunz Germany 12 46 0.4× 74 0.8× 217 2.6× 79 1.1× 38 0.7× 49 523
André W. Broekmans Netherlands 8 152 1.4× 64 0.7× 51 0.6× 34 0.5× 32 0.6× 15 828
Karen Lien Canada 14 41 0.4× 53 0.6× 27 0.3× 31 0.4× 96 1.8× 20 446
Frank van Bockxmeer Australia 13 103 1.0× 28 0.3× 59 0.7× 53 0.7× 27 0.5× 25 508
Payal Shah United States 14 49 0.5× 34 0.4× 32 0.4× 67 0.9× 40 0.8× 54 588
Anas Zakarya Nourelden Egypt 13 40 0.4× 17 0.2× 65 0.8× 46 0.6× 26 0.5× 36 415
Camilla Normand Norway 9 232 2.2× 20 0.2× 47 0.6× 30 0.4× 107 2.1× 25 624
Pamela Landsman‐Blumberg United States 11 32 0.3× 32 0.4× 52 0.6× 55 0.8× 44 0.8× 34 302
Liliana Gazzuola Rocca United States 13 17 0.2× 39 0.4× 82 1.0× 27 0.4× 37 0.7× 30 535
Li-Kuei Chen Taiwan 16 57 0.5× 40 0.4× 63 0.8× 140 1.9× 17 0.3× 52 674

Countries citing papers authored by Kate Gelperin

Since Specialization
Citations

This map shows the geographic impact of Kate Gelperin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Gelperin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Gelperin more than expected).

Fields of papers citing papers by Kate Gelperin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Gelperin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Gelperin. The network helps show where Kate Gelperin may publish in the future.

Co-authorship network of co-authors of Kate Gelperin

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Gelperin. A scholar is included among the top collaborators of Kate Gelperin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Gelperin. Kate Gelperin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Bird, Steven T., Kate Gelperin, Elizabeth R. Smith, et al.. (2024). The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease. Annals of Internal Medicine. 178(1). 29–38. 10 indexed citations
2.
Bird, Steven T., Elizabeth R. Smith, Kate Gelperin, et al.. (2024). Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients. JAMA. 331(6). 491–491. 30 indexed citations
3.
Winterstein, Almut G., Thuy Nhu Thai, Sabina O. Nduaguba, et al.. (2022). Risk of fetal or neonatal death or neonatal intensive care unit admission associated with gadolinium magnetic resonance imaging exposure during pregnancy. American Journal of Obstetrics and Gynecology. 228(4). 465.e1–465.e11. 22 indexed citations
4.
Bird, Steven T., Donna Przepiorka, Rongrong Wang, et al.. (2019). Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia. JAMA Oncology. 6(2). 248–248. 41 indexed citations
5.
Bird, Steven T., Kate Gelperin, Leyla Şahin, et al.. (2019). First-Trimester Exposure to Gadolinium-based Contrast Agents: A Utilization Study of 4.6 Million U.S. Pregnancies. Radiology. 293(1). 193–200. 40 indexed citations
6.
Bird, Steven T., Ólanrewaju O. Okusanya, Peter Waldron, et al.. (2018). Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies. The Lancet Child & Adolescent Health. 3(1). 15–22. 12 indexed citations
7.
Bird, Steven T., Sengwee Toh, Leyla Şahin, et al.. (2018). Misclassification in Assessment of First Trimester In-utero Exposure to Drugs Used Proximally to Conception: the Example of Letrozole Utilization for Infertility Treatment. American Journal of Epidemiology. 188(2). 418–425. 10 indexed citations
8.
Toh, Sengwee, Susan E. Andrade, Christian Hampp, et al.. (2018). Utilization of drugs with pregnancy exposure registries during pregnancy. Pharmacoepidemiology and Drug Safety. 27(6). 604–611. 9 indexed citations
9.
Bird, Steven T., Kate Gelperin, Lockwood G. Taylor, et al.. (2017). Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer’s Capture of Spontaneous Reports for Exposed Pregnancies. Drug Safety. 41(1). 87–94. 21 indexed citations
10.
Gelperin, Kate, Hoda T. Hammad, Kira Leishear, et al.. (2016). A systematic review of pregnancy exposure registries: examination of protocol-specified pregnancy outcomes, target sample size, and comparator selection. Pharmacoepidemiology and Drug Safety. 26(2). 208–214. 32 indexed citations
11.
12.
Graham, David J., Esther H. Zhou, Stephen McKean, et al.. (2013). Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers. Pharmacoepidemiology and Drug Safety. 23(4). 331–339. 10 indexed citations
13.
Mosholder, Andrew D., et al.. (2009). Hallucinations and Other Psychotic Symptoms Associated With the Use of Attention-Deficit/Hyperactivity Disorder Drugs in Children. PEDIATRICS. 123(2). 611–616. 96 indexed citations
14.
Sharma, Satish, et al.. (1999). The Hemodynamic Effects of Long-Term ACE Inhibition with Fosinopril in Patients with Heart Failure. American Journal of Therapeutics. 6(4). 181–190. 4 indexed citations
15.
Brown, Edward J., et al.. (1995). Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. The American Journal of Cardiology. 75(8). 596–600. 32 indexed citations
16.
Erhardt, Leif, et al.. (1995). Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. European Heart Journal. 16(12). 1892–1899. 63 indexed citations
17.
Kipen, Howard M., et al.. (1991). Acute occupational respiratory diseases in hospital discharge data. American Journal of Industrial Medicine. 19(5). 637–642. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Kunz Breakdown of academic impact, for papers by André W. Broekmans Breakdown of academic impact, for papers by Karen Lien Breakdown of academic impact, for papers by Frank van Bockxmeer Breakdown of academic impact, for papers by Payal Shah Breakdown of academic impact, for papers by Anas Zakarya Nourelden Breakdown of academic impact, for papers by Camilla Normand Breakdown of academic impact, for papers by Pamela Landsman‐Blumberg Breakdown of academic impact, for papers by Liliana Gazzuola Rocca Breakdown of academic impact, for papers by Li-Kuei Chen
Rankless by CCL
2026